InterMune ascends on Esbriet sales, Phase III progress
This article was originally published in Scrip
InterMune's stock closed at its highest price this year after the company's second quarter earnings report suggested that everything finally is moving into place for the idiopathic pulmonary fibrosis (IPF) drug Esbriet (pirfenidone).
You may also be interested in...
Clinical trials in a range of diseases continue to be impacted by concerns about patient safety and health care resources as the COVID-19 pandemic grows.
ReCode, whose platform allows for organ-specific delivery of RNA therapies, plans to start clinical trials in 2022 for its two lead programs in primary ciliary dyskinesia and cystic fibrosis.
Public Company Edition: Benefitting from hope that biopharma interventions will help the coronavirus pandemic, the industry is faring better than others in the stock market, including the ability to launch IPOs. Also, BridgeBio leads recent financings and PDL is on track to dissolve by year-end.